PROSPECTIVE COMPARATIVE-STUDY IN NIDDM PATIENTS OF METFORMIN AND GLIBENCLAMIDE WITH SPECIAL REFERENCE TO LIPID PROFILES

被引：37

作者：

HERMANN, LS

KARLSSON, JE

SJOSTRAND, A

机构：

[1] UNIV LUND,DEPT RES PRIMARY HLTH CARE,DALBY,SWEDEN

[2] JONKOPING CTR HOSP,DEPT MED,JONKOPING,SWEDEN

[3] TRANAS HOSP,MED CLIN,TRANAS,SWEDEN

来源：

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 1991年 / 41卷 / 03期

关键词：

METFORMIN; GLIBENCLAMIDE; NIDDM; LIPOPROTEINS; C-PEPTIDE; DIABETES-MELLITUS; ADVERSE EFFECTS; SERUM LIPIDS;

D O I：

10.1007/BF00315441

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Twenty-two NIDDM patients completed an open randomized cross-over study comparing metformin and glibenclamide over 1 year. The drugs had an equivalent effect on glycaemic control, but, in contrast to glibenclamide, metformin reduced body weight. Neither drug affected triglycerides, total- and LDL-cholesterol or C-peptide. Metformin caused a slight elevation of HDL-cholesterol (P < 0.05). No serious adverse effects were observed. The results show that oral hypoglycaemic agents are not associated with undesirable effects on lipids and lipoproteins.

引用

页码：263 / 265

页数：3

共 8 条

[1] LIPIDS, DIABETES, AND VASCULAR-DISEASE - THE TIME TO ACT [J].